Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance After Induction With Carfilzomib-Cyclophosphamide-Dexamethasone In Salvage Asct In Multiple Myeloma: A Trial By The Nordic Myeloma Study Group

Henrik Gregersen,Valdas Peceliunas,Kari Remes,Fredrik H. Schjesvold,Niels Abildgaard,Hareth Nahi,Niels Frost Andersen,Annette Juul Vangsted,Tobias Wirenfeldt Klausen,Carsten Helleberg,Kristina Carlson,Ulf Christian Frolund,Per Axelsson,Olga Stromberg,Cecilie Hveding Blimark,Olle Linder,Galina Tsykunova,Anders Waage,Markus Hansson,Nina Gulbrandsen

BLOOD（2019）

Cited 6|Views18
No score
Abstract
Background: Salvage autologous stem cell transplantation (ASCT) is used in selected patients with relapsed multiple myeloma after up-front ASCT. However, there are limited data on the optimal induction therapy before salvage ASCT. There is strong support for the use of maintenance therapy after upfront ASCT in newly diagnosed multiple myeloma whereas data on maintenance therapy after salvage ASCT are sparse.
More
Translated text
Key words
multiple myeloma,carfilzomib-dexamethasone,carfilzomib-cyclophosphamide-dexamethasone
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined